Dexmedetomidine an Effective Drug in Reducing Anesthetic Requirements in External Dacrocystorhinostomy (DCR) Patients

Research Institute of Ophthalmology, Egypt

Status and phase: Enrolling; Phase 1

Conditions: Patients Undergoing External Dacrocystorhinostomy Operations; Assess Decreased Anesthetic Requirements Intraoperative

Treatments: Drug: Dexmedetomidine Hydrochloride

Study type: Interventional

Funder types: Other

Identifiers

NCT06808295

24-11-17-6-5

Details and patient eligibility

About

Assessing the intra and postoperative hemodynamic stability in patients undergoing external dacrocystorhinostomy under general anesthesia using Dexmedetomidine as a preoperative sedation compared to traditional technique with intraoperative analgesia and assessing decreased anesthetic requirements intra and postoperative

Full description

Dexmedetomidine is a highly selective alpha 2 adrenoceptor agonist, having characteristics of natural sleep like sedation, can reduce pain intensity and opioid consumption without influencing the time of recovery from general anesthesia

Enrollment: 24 estimated patients

Sex: All

Ages: 16 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

patients of both sexes 16 years to 75 years of age ASA (American society of Anesthesiologists) I-III

Exclusion criteria

• Pediatric age group
• ASA more than III

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

24 participants in 2 patient groups

Dexmedetomidine

Active Comparator group

Description:

Dexmedetomidine 0.25 microgram per kilogram is used in Dacrocystorhinostomy patients 20 minutes before induction of general anesthesia

Treatment:

Drug: Dexmedetomidine Hydrochloride

Control

No Intervention group

Description:

Fentanyl as an analgesic is used with general anesthesia in Dacrocystorhinostomy patients